Rigel Pharmaceuticals Inc (RIGL)

2.63
NASDAQ : Health Care
Prev Close 2.63
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.88 / 4.38
Avg Volume 1.37M
Exchange NASDAQ
Shares Outstanding 98.94M
Market Cap 262.18M
EPS -0.60
P/E Ratio 6.02
Div & Yield N.A. (N.A)

Latest News

Rigel Expands Leadership Team In Research And Business Development

Rigel Expands Leadership Team In Research And Business Development

Reaffirms research focus and IRAK program plans

Short Interest Moves 115.3% Higher For RIGL

Short Interest Moves 115.3% Higher For RIGL

The most recent short interest data has been released for the 09/15/2016 settlement date, which shows a 2,693,273 share increase in total short interest for Rigel Pharmaceuticals Inc , to 5,029,294, an increase of 115.29% since 08/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Interesting RIGL Put And Call Options For November 18th

Interesting RIGL Put And Call Options For November 18th

Investors in Rigel Pharmaceuticals Inc saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the RIGL options chain for the new November 18th contracts and identified one put and one call contract of particular interest.

Rigel Restructures To Focus On Fostamatinib Commercialization

Rigel Restructures To Focus On Fostamatinib Commercialization

Hires Eldon Mayer as first Chief Commercial Officer, Founder Donald Payan Retires

Rigel Pharma (RIGL) Stock Jumps on Study Results, Piper Jaffray Ups Price Target

Rigel Pharma (RIGL) Stock Jumps on Study Results, Piper Jaffray Ups Price Target

Piper Jaffray increased its price target on Rigel Pharma (RIGL) stock on Tuesday following a late-stage study win for an experimental drug.

Markets Very Sluggish as August Nears an End

Markets Very Sluggish as August Nears an End

Even concerns about a possible Fed rate hike do not appear to be affecting traders.

Rigel Pharma Claims Late-Stage Study Win for Blood Platelet Drug

Rigel Pharma Claims Late-Stage Study Win for Blood Platelet Drug

The 18% response rate for fostamatinib in the Rigel phase III study was on the lower end of investor expectations.

Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP

Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP

Conference call and webcast today at 8:00 AM Eastern Time

Rigel Pharmaceuticals (RIGL) Weak On High Volume Today

Rigel Pharmaceuticals (RIGL) Weak On High Volume Today

Trade-Ideas LLC identified Rigel Pharmaceuticals (RIGL) as a weak on high relative volume candidate

Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer

Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer

Elliott Grossbard, M.D. Retires; Continues Advising on Fostamatinib in the ITP Program